Wells Fargo Stays Bullish on NeuroPace, Sets Price Target at $20
Wednesday, 29 May 2024, 16:05
Wells Fargo Reaffirms Overweight Rating on NeuroPace with $20 Target
Wells Fargo has reiterated an Overweight rating on NeuroPace and maintains a target price of $20. This decision reflects Wells Fargo's positive outlook on the neurotechnology company's future prospects.
Key Points:
- Wells Fargo remains bullish on NeuroPace
- Price target set at $20
- Confidence in the company's growth potential
Investors may consider NeuroPace as a potential opportunity for growth within their portfolio.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.